| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF4A1 |
| Uniprot No | P60842 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-406aa |
| 氨基酸序列 | SASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI |
| 预测分子量 | 53.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Functional characterization of recombinant eukaryotic initiation factor 4A1 (eIF4A1) using biochemical assays"** by Hernandez, G. et al.
*摘要：研究通过大肠杆菌重组表达并纯化EIF4A1蛋白，验证其ATP酶活性及RNA解旋酶功能，揭示其在翻译起始中的分子机制。*
2. **"eIF4A1 enhances translational efficiency of oncogenic mRNAs in cancer cells"** by Fraser, C.S. et al.
*摘要：利用重组EIF4A1蛋白结合体外翻译系统，证明其通过选择性解旋特定mRNA二级结构促进癌细胞关键基因(如c-MYC)的高效翻译。*
3. **"Targeting eIF4A1 with natural compound inhibitors identified via high-throughput screening"** by Park, S.H. et al.
*摘要：基于重组EIF4A1蛋白建立高通量筛选平台，鉴定出小分子抑制剂(如银椴苷)，抑制其解旋酶活性并展示抗癌潜力。*
4. **"Structural insights into eIF4A1 mechanism during ribosome scanning"** by Andreou, A.Z. et al.
*摘要：通过X射线晶体学解析重组EIF4A1蛋白的构象变化，阐明其与RNA及eIF4G结合时的动态调节，为靶向药物设计提供结构基础。*
(注：上述文献信息为示例性概括，实际引用需以具体论文为准。)
EIF4A1. a member of the Eukaryotic Translation Initiation Factor 4A (eIF4A) family, is a DEAD-box RNA helicase critical for protein synthesis in eukaryotic cells. As an ATP-dependent RNA helicase, it plays a central role in translation initiation by resolving secondary structures in mRNA 5′-untranslated regions (UTRs), enabling ribosome binding and scanning. EIF4A1 functions as part of the eIF4F complex, alongside eIF4E (cap-binding protein) and eIF4G (scaffolding protein), to facilitate the assembly of translation machinery. Its helicase activity is tightly regulated to maintain cellular homeostasis, with dysregulation linked to cancers, neurological disorders, and viral infections.
Recombinant EIF4A1 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) for functional and structural studies. Purified recombinant variants often include affinity tags (e.g., His-tag) to streamline isolation. Researchers utilize this protein to investigate translation mechanisms, screen for inhibitors (e.g., natural compounds like silvestrol or synthetic molecules), and study viral hijacking of host translation pathways. In cancer research, EIF4A1 is a therapeutic target due to its overexpression in certain malignancies and role in promoting oncoprotein synthesis. Structural analyses of recombinant EIF4A1 have revealed conformational dynamics during ATP/RNA binding, informing drug design. Recent studies also explore its non-canonical roles in stress granule formation and RNA metabolism. The development of catalytically active recombinant EIF4A1 continues to advance both basic research and translational applications in diseases tied to dysregulated translation.
×
